Reviewing IN8bio (NASDAQ:INAB) and OKYO Pharma (NASDAQ:OKYO)

IN8bio (NASDAQ:INAB) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for IN8bio and OKYO Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	0	0	1	0	3.00
OKYO Pharma	0	0	1	0	3.00

IN8bio currently has a consensus price target of $6.00, indicating a potential upside of 2,476.21%. OKYO Pharma has a consensus price target of $7.00, indicating a potential upside of 455.56%. Given IN8bio’s higher probable upside, equities analysts plainly believe IN8bio is more favorable than OKYO Pharma.

Institutional and Insider Ownership

92.1% of IN8bio shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 15.5% of IN8bio shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares IN8bio and OKYO Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-197.15%	-130.48%
OKYO Pharma	N/A	N/A	N/A

Volatility and Risk

IN8bio has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.34, indicating that its share price is 134% less volatile than the S&P 500.

Earnings & Valuation

This table compares IN8bio and OKYO Pharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$30.01 million	($0.58)	-0.40
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A

Summary

OKYO Pharma beats IN8bio on 4 of the 7 factors compared between the two stocks.

About IN8bio

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.